Welcome to our dedicated page for Seres Therapeutics SEC filings (Ticker: MCRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Seres Therapeutics, Inc. (MCRB) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents include Form 8-K current reports, which Seres uses to announce quarterly financial results, operational updates, leadership changes, cost-reduction actions, and other material events.
For a clinical-stage live biotherapeutics company like Seres, SEC filings are a primary source of information on the status of its programs and financial position. In recent 8-K filings, the company has reported results and updates related to its lead investigational candidate SER-155, including descriptions of Phase 1b data in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT), regulatory designations such as Breakthrough Therapy and Fast Track, and ongoing interactions with the U.S. Food and Drug Administration regarding a planned Phase 2 study design.
Filings also discuss the company’s classification of historical VOWST™ operating results as discontinued operations following the sale of that asset to Nestlé Health Science, as well as the provision of manufacturing services under a Transition Services Agreement. Additional disclosures cover cash runway expectations, workforce reductions, and business development efforts aimed at securing capital or strategic partnerships to advance SER-155 and other live biotherapeutic candidates.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand topics such as trial plans, risk factor discussions, and material corporate actions. Users can review 8-Ks and other filings in real time as they are posted to EDGAR, and use AI-generated insights to interpret how Seres’ regulatory and financial disclosures relate to its live biotherapeutics pipeline and overall strategy.